Skip to main content

Advertisement

Log in

FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis

  • Image of the Month
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Flechsig P, Mehndiratta A, Haberkorn U, Kratochwil C, Giesel FL. PET/MRI and PET/CT in lung lesions and thoracic malignancies. Semin Nucl Med. 2015;45(4):268–81. https://doi.org/10.1053/j.semnuclmed.2015.03.004.

    Article  PubMed  Google Scholar 

  2. Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59(9):1415–22. https://doi.org/10.2967/jnumed.118.210443.

    Article  CAS  PubMed  Google Scholar 

  3. Loktev A, Lindner T, Mier W, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59(9):1423–9. https://doi.org/10.2967/jnumed.118.210435.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Giesel F, Kratochwil C, Lindner T, et al. FAPI-PET/CT: biodistribution and preliminary dosimetry estimate of two DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60(3):386–392. https://doi.org/10.2967/jnumed.118.215913.

  5. Kratochwil C, Flechsig P, Lindner T, et al. FAPI-PET/CT: mean intensity of tracer-uptake (SUV) in 28 different kinds of cancer. J Nucl Med 2019 6. doi: https://doi.org/10.2967/jnumed.119.227967.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Clemens Kratochwil.

Ethics declarations

Informed consent and ethical approval

The radiopharmaceutical was used on an individual patient basis according to German Pharmaceuticals Act §13(2b). The patient gave written informed consent to receive the novel diagnostics and permitted anonymized publication of related medical data. The ethical committee of Heidelberg University approved this retrospective evaluation to be in accordance with the Helsinki declaration (permit S016/2018). For case reports from clinical practice no trial registration is required.

Disclosure of potential conflicts of interest

Giesel FL, Lindner T, Haberkorn U, Kratochwil C have a patent application for quinolone-based radiolabeled FAPI-ligands. The other authors have no conflict of interest to declare.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Image of the Month.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Giesel, F.L., Heussel, C.P., Lindner, T. et al. FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis. Eur J Nucl Med Mol Imaging 46, 1754–1755 (2019). https://doi.org/10.1007/s00259-019-04346-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-019-04346-z

Navigation